Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2001
Letter to the Editor: Ms Robinson and colleagues
recently summarized data from the Active Bacterial Core Surveillance/Emerging
Infections Program Network to understand the epidemiology of Streptococcus pneumoniae in invasive pneumococcal disease (IPD).1 The authors state, "We sought to estimate the expected
effect of the recently licensed vaccine [7-valent pneumococcal conjugate vaccine]
. . . " and, "More than half of these cases [IPD] occurred in adults who had
an indication for pneumococcal polysaccharide vaccination . . . " However,
it is important to note that the "expected effect" and actual effectiveness
of pneumococcal vaccination may differ markedly.
Artz AS, Ershler WB. Pneumococcal Vaccination in Adults. JAMA. 2001;286(2):166-167. doi:10.1001/jama.286.2.166